NLRX1 and metabolic dysfunction-associated steatotic liver disease: Recent studies have reported that NLRX1 may limit fatty acid oxidation (FAO) and promote glycolysis in hepatocytes from a non-alcoholic fatty liver disease (NAFLD) model (19), or reduce mitochondrial oxygen consumption in kidney epithelial cells (8).